Tag: life sciences
-
State Grant Funds Virus-Immunotherapy Cancer Trial
A California state agency is helping fund a clinical trial testing an immunotherapy combined with a cancer-killing virus to treat solid tumor cancers.
-
Early Trials Show Responses for Some Blood Cancers
First results from two clinical trials testing the safety of natural killer cell therapies show responses by patients with some forms of blood-related cancers.
-
Ginkgo Acquires Bayer Agricultural Biologics Technology
Synthetic biology developer Ginkgo Bioworks is acquiring agricultural biologics assets from Bayer, transforming the companies’ five-year partnership.
-
Trial Begins Testing Crispr Gut Microbiome Therapy
A clinical trial is underway assessing a genetically edited oral drug designed to remove E. coli in the gut, a danger for patients with blood-related cancers.
-
Cystic Fibrosis Start-Up Raises $111M in New Funds
A developer of new treatments for the inherited lung disease cystic fibrosis emerged from stealth mode, raising $111 million in new venture funds.
-
Trial Set for Gut Infection Biologic Treatment
A developer of biologic therapies for gastrointestinal disorders says FDA cleared its request for a clinical trial testing its treatment for C. difficile.
-
Biotech Start-Up Begins Longevity Therapy Work
A new biotechnology company has begun developing gene therapies aimed at reprogramming cells damaged by the aging process.
-
Gates Funds Engineered Malaria Mosquito Pilot Test
A developer of genetically altered insects designed to destroy disease-spreading colonies is set to begin pilot tests of its anti-malarial mosquito line.
-
Preclinical Tests Show Antibody Stops Covid-19 Variants
Lab studies show an experimental synthetic antibody protects animals and neutralizes all SARS-CoV-2 variants of concern, including omicron BA.2.
-
Synthetic Bio Companies Partner on Therapeutic Microbes
A developer of therapies from engineered microbes is collaborating with a synthetic biology components company on tools to create engineered gut bacteria.